Vnitr Lek 1993, 39(5):445-450

[Erythropoietin or transfusion?].

V Bártová, K Němecek, J Lachmanová: II. interní klinika 1. LF UK, Praha.

Klíčová slova: Adolescent; Adult; Aged; Anemia, etiology, ; Blood Transfusion; Erythropoietin, therapeutic use, ; Humans; Middle Aged; Renal Dialysis, adverse effects,

The cause of anaemia in dialyzed patients is multifactorial. In the submitted paper the authors give an account of their experience with the treatment of 40 patients with erythropoietin (Eprex Cilag Co.). The initial Hb values were 78 +/- 13 g/l and haematocrit 0.24 +/- 0.03. After three months of treatment the haematocrit values were 0.30 +/- 0.02 and the Hb values 103 +/- 7 g/l. After one year's treatment haematocrit values were 0.31 +/- 0.03, Hb 105 +/- 10 g/l. Treatment was started by administration of 150 u/kg/week. Despite considerable individual differences the mean maintenance dose after one-year treatment is only 65 u/kg/week. In two patients treatment was discontinued. Treatment of anaemia in dialyzed patients with erythropoietin is effective and as compared with the risks of repeated transfusions, also economical.